Posted 08 January 2014
By Alexander Gaffney, RAC
Even by the usual standards of the US Food and Drug Administration (FDA), it has been an unusually busy week for announcing advisory committee meetings.
The committees, which offer regulators non-binding but influential advice that is generally followed, are often called upon to either assess new products or niche problems requiring specialized or public input.
This week has already seen a flurry of announcements for upcoming advisory committee meetings, with no fewer than nine meetings scheduled since 31 December 2013. A listing of those meetings and brief summaries of their respective topics may be found below, as well as two additional meetings scheduled the week prior.